MADRIGAL PHARMACEUTICALS, INC. Diluted Shares Outstanding (Weighted Average)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Diluted Shares Outstanding (Weighted Average) of 29.15 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 29.15M shares, a 3.23% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 29.03M shares, a 3.37% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 28.81M shares, a 35.23% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 28.51M shares, a 31.10% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 17.14M shares, a 3.64% increase from fiscal 2021.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for fiscal 2021 was 16.54M shares, a 7.05% increase from fiscal 2020.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for fiscal 2020 was 15.45M shares.
- MADRIGAL PHARMACEUTICALS, INC. weighted average number of shares outstanding, diluted for fiscal 2011 was 47.20M shares, a 16.93% increase from fiscal 2010.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 29.15M shares 10-Q · filed 2026-07-30 | 29.09M shares 10-Q · filed 2026-07-30 | 29.00M shares derived: average of 3 quarters · filed 2026-07-30 | 28.87M shares derived: average of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | 29.03M shares 10-Q · filed 2026-05-06 | 28.92M shares derived: average of 2 quarters · filed 2026-07-30 | 28.78M shares derived: average of 3 quarters · filed 2026-07-30 | 28.65M shares derived: average of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | 28.81M shares derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | 28.66M shares derived: average of 2 quarters · filed 2026-07-30 | 28.52M shares derived: average of 3 quarters · filed 2026-07-30 | 28.41M shares 10-Q · filed 2026-07-30 | 22.43M shares 10-K · filed 2026-02-19 | |||
| 2025-09-30 | 28.51M shares 10-Q · filed 2026-07-30 | 22.48M shares 10-Q · filed 2025-11-04 | 28.37M shares derived: average of 2 quarters · filed 2026-07-30 | 28.28M shares 10-Q · filed 2026-07-30 | 22.26M shares 10-Q · filed 2025-11-04 | 32.33M shares derived: average of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | 28.23M shares 10-Q · filed 2026-07-30 | 22.21M shares 10-Q · filed 2025-08-05 | 28.16M shares 10-Q · filed 2026-07-30 | 22.15M shares 10-Q · filed 2025-08-05 | 33.60M shares derived: average of 3 quarters · filed 2026-07-30 | 30.63M shares derived: average of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | 28.09M shares 10-Q · filed 2026-05-06 | 22.09M shares 10-Q · filed 2025-05-01 | 36.28M shares derived: average of 2 quarters · filed 2026-07-30 | 31.44M shares derived: average of 3 quarters · filed 2026-07-30 | 28.93M shares derived: average of 4 quarters · filed 2026-07-30 | |||
| 2024-12-31 | 44.47M shares derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | 33.11M shares derived: average of 2 quarters · filed 2026-07-30 | 29.21M shares derived: average of 3 quarters · filed 2026-07-30 | 26.91M shares 10-Q · filed 2026-07-30 | 21.27M shares 10-K · filed 2025-02-26 | |||
| 2024-09-30 | 21.75M shares 10-Q · filed 2025-11-04 | 21.57M shares derived: average of 2 quarters · filed 2025-11-04 | 21.05M shares 10-Q · filed 2025-11-04 | 20.73M shares derived: average of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | 21.40M shares 10-Q · filed 2025-08-05 | 20.70M shares 10-Q · filed 2025-08-05 | 20.39M shares derived: average of 3 quarters · filed 2025-08-05 | 19.91M shares derived: average of 4 quarters · filed 2025-08-05 | ||||
| 2024-03-31 | 20.00M shares 10-Q · filed 2025-05-01 | 19.88M shares derived: average of 2 quarters · filed 2025-05-01 | 19.41M shares derived: average of 3 quarters · filed 2025-05-01 | 19.14M shares derived: average of 4 quarters · filed 2025-05-01 | ||||
| 2023-12-31 | 19.76M shares 10-K · filed 2024-02-28 | 19.12M shares derived: average of 2 quarters · filed 2024-10-31 | 18.85M shares derived: average of 3 quarters · filed 2024-10-31 | 21.56M shares 10-Q · filed 2026-07-30 | 18.69M shares 10-K · filed 2024-02-28 | |||
| 2023-09-30 | 18.48M shares 10-Q · filed 2024-10-31 | 18.39M shares derived: average of 2 quarters · filed 2024-10-31 | 18.33M shares 10-Q · filed 2024-10-31 | 18.05M shares derived: average of 4 quarters · filed 2024-10-31 | ||||
| 2023-06-30 | 18.31M shares 10-Q · filed 2024-08-07 | 18.25M shares 10-Q · filed 2024-08-07 | 17.91M shares derived: average of 3 quarters · filed 2024-08-07 | 17.71M shares derived: average of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | 18.19M shares 10-Q · filed 2024-05-07 | 17.71M shares derived: average of 2 quarters · filed 2024-05-07 | 17.51M shares derived: average of 3 quarters · filed 2024-05-07 | 17.41M shares derived: average of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | 17.24M shares 10-K · filed 2024-02-28 | 17.17M shares derived: average of 2 quarters · filed 2024-02-28 | 17.15M shares derived: average of 3 quarters · filed 2024-02-28 | 17.14M shares 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | 17.10M shares 10-K · filed 2024-02-28 | 17.10M shares derived: average of 2 quarters · filed 2024-02-28 | 17.10M shares 10-Q · filed 2023-11-06 | 17.10M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | 17.10M shares 10-K · filed 2024-02-28 | 17.10M shares 10-Q · filed 2023-08-08 | 17.09M shares derived: average of 3 quarters · filed 2024-02-28 | 16.98M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | 17.10M shares 10-K · filed 2024-02-28 | 17.09M shares derived: average of 2 quarters · filed 2024-02-28 | 16.94M shares derived: average of 3 quarters · filed 2024-02-28 | 16.85M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | 17.07M shares 10-K/A · filed 2023-03-03 | 16.86M shares derived: average of 2 quarters · filed 2023-03-03 | 16.76M shares derived: average of 3 quarters · filed 2023-03-03 | 16.54M shares 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | 16.64M shares 10-K/A · filed 2023-03-03 | 16.61M shares derived: average of 2 quarters · filed 2023-03-03 | 16.35M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 16.57M shares 10-K/A · filed 2023-03-03 | 16.21M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 15.84M shares 10-K/A · filed 2023-03-03 | 16.57M shares 10-Q · filed 2022-08-04 | ||||||
| 2020-12-31 | 15.45M shares 10-K/A · filed 2023-03-03 | |||||||
| 2012-03-31 | 56.37M shares 10-Q · filed 2012-05-03 | 59.38M shares derived: average of 2 quarters · filed 2012-05-03 | 53.66M shares derived: average of 3 quarters · filed 2012-05-03 | 50.79M shares derived: average of 4 quarters · filed 2012-05-03 | ||||
| 2011-12-31 | 62.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | 52.31M shares derived: average of 2 quarters · filed 2012-02-22 | 48.93M shares derived: average of 3 quarters · filed 2012-02-22 | 47.20M shares 10-K · filed 2012-02-22 | ||||
| 2011-09-30 | 42.21M shares 10-Q · filed 2011-11-03 | 42.19M shares derived: average of 2 quarters · filed 2011-11-03 | 42.13M shares 10-Q · filed 2011-11-03 | 41.92M shares derived: average of 4 quarters · filed 2012-05-03 | ||||
| 2011-06-30 | 42.17M shares 10-Q · filed 2011-08-04 | 42.09M shares 10-Q · filed 2011-08-04 | 41.82M shares derived: average of 3 quarters · filed 2012-05-03 | 41.46M shares derived: average of 4 quarters · filed 2012-05-03 | ||||
| 2011-03-31 | 42.01M shares 10-Q · filed 2012-05-03 | 41.64M shares derived: average of 2 quarters · filed 2012-05-03 | 41.22M shares derived: average of 3 quarters · filed 2012-05-03 | 41.00M shares derived: average of 4 quarters · filed 2012-05-03 | ||||
| 2010-12-31 | 41.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | 40.83M shares derived: average of 2 quarters · filed 2012-02-22 | 40.67M shares derived: average of 3 quarters · filed 2012-02-22 | 40.37M shares 10-K · filed 2012-02-22 | ||||
| 2010-09-30 | 40.38M shares 10-Q · filed 2011-11-03 | 40.36M shares derived: average of 2 quarters · filed 2011-11-03 | 40.06M shares 10-Q · filed 2011-11-03 | |||||
| 2010-06-30 | 40.34M shares 10-Q · filed 2011-08-04 | 39.90M shares 10-Q · filed 2011-08-04 | ||||||
| 2009-12-31 | 34.12M shares 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |